Angina or ischemia with no obstructed coronary arteries: a specific diagnostic and therapeutic protocol

Riccardo Rinaldi,‡ Francesco Spione,†,◊ Filippo Maria Verardi,†,◊ Pablo Vidal Calés,† Víctor Arévalos,† Rami Gabani,† Daniel Cánovas,† Montserrat Gutiérrez,† Montserrat Pardo,† Rosa Domínguez,† Luis Pinto,† Xavier Torres,‡ Xavier Freixa,† Ander Regueiro,† Omar Abdul-Jawad Altisent,† Manel Sabaté,† and Salvatore Brugaletta†,*

†Hospital Clinic, Instituto Clinic Cardiovascular, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
‡Dipartimento di Scienze Cardiovascolari e Polmonari, Università Cattolica del Sacro Cuore, Rome, Italy
◊Servizio di Cardiologia Interventistica, Clinica Montevergine, Mercogliano, Italy
dDipartimento di Scienze Biomediche Avanzate, Università di Napoli, Federico II, Naples, Italy
eDipartimento di Cardiologia, Azienda ospedaliero-universitaria di Ferrara, Cona, Ferrara, Italy
fInstituto de Psiquiatría, Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
gServicio de Psiquiatría y Psicología Infantil y Juvenil, Institut Clínic de Neurociències, Barcelona, Spain

SEE RELATED CONTENT: https://doi.org/10.24875/RECICE.M23000433

ABSTRACT

Introduction and objectives: A systematic approach to patients with angina with no obstructed coronary arteries (ANOCA) or ischemia with no obstructed coronary arteries (INOCA) patients is not routinely implemented.

Methods: All consecutive patients diagnosed with ANOCA/INOCA were referred to a designated outpatient clinic for a screening visit to assess their eligibility for a NOCA program. If eligible, patients underwent scheduled coronary angiograms with coronary function testing and intracoronary acetylcholine provocation testing. Medical therapy was optimized accordingly. All patients were then followed up at 1, 3, 6, and 12 months. Baseline and 3-month follow-up assessments included the Seattle Angina Questionnaire (SAQ) and EuroQol-5D questionnaire.

Results: Of 77 patients screened, 23 (29.9%) were excluded and 54 (70.1%) were included (29 [53.7%] with INOCA and 25 [46.3%] with ANOCA). Microvascular angina was diagnosed in 19 (35.2%) patients, vasospastic angina in 12 (22.2%), both microvascular angina and vasospastic angina in 18 (33.3%), and noncoronary chest pain in 5 (9.3%). There was a notable increase in the use of beta-blockers, calcium channel blockers and nitrates. Complications occurred in 3 (5.5%) patients. Compared with baseline, there was no difference in the mean EQ-5D score at the 3-month follow-up, but there was a significant improvement in the SAQ score related to physical limitations, angina stability, and disease perception, with no differences in angina frequency or treatment satisfaction. No events were recorded at the 1-year follow-up.

Conclusions: A specific diagnostic and therapeutic protocol can be easily and safely implemented in routine clinical practice, leading to improvement in patients’ quality of life.

Keywords: INOCA. ANOCA. Diagnosis. Therapy. Protocol.

Angina o isquemia con arterias coronarias no obstruidas: un protocolo diagnóstico y terapéutico específico

RESUMEN

Introducción y objetivos: El abordaje sistemático en pacientes con angina con arterias coronarias no obstruidas (ANOCA) o con isquemia con arterias coronarias no obstruidas (INOCA) no está bien protocolizado.

Métodos: Todos los pacientes con diagnóstico de INOCA o ANOCA se trasladaron a una clínica ambulatoria específica para evaluar su elegibilidad para el programa NOCA. Si eran elegibles, se sometían a una angiografía coronaria programada con pruebas de función coronaria y provocación intracoronaria con acetilcolina. La terapia médica se optimizó en consecuencia. Todos los pacientes tuvieron un seguimiento a 1, 3, 6 y 12 meses. Al inicio y a los 3 meses se aplicaron los cuestionarios SAQ y EuroQol-5D.

Keywords: INOCA. ANOCA. Diagnosis. Therapy. Protocol.
INTRODUCTION

Ischemic heart disease is the leading cause of disability and mortality worldwide and is commonly characterized by the presence of obstructive coronary artery disease (CAD) (defined as any coronary artery stenosis ≥ 50% in diameter). However, up to 60% to 70% of patients with angina and/or documented myocardial ischemia do not have angiographic evidence of CAD. This condition is defined as angina with no obstructed coronary arteries (ANOCA) or ischemia with no obstructed coronary arteries (INOCA) when associated with evidence of myocardial ischemia. Of note, despite the absence of CAD, these patients are at an increased risk of future cardiovascular events such as acute coronary syndrome, heart failure hospitalization, stroke, and repeat cardiovascular procedures compared with healthy individuals. Therefore, appropriate management in terms of diagnosis and treatment is of the utmost importance to improve patients’ prognosis and outcomes. The CoroFlow Cardiovascular System, Abbott Vascular, United States) tailored therapy. During the counseling sessions, the predicted benefits and low associated risks of an invasive procedure to specifically study coronary microcirculation and vasospasm were explained in detail. All patients provided written informed consent to be included in this program and study. The clinical ethics committee gave their approval for a retrospective analysis of the collected data.

METHODS

Eligibility criteria for the NOCA program

All consecutive patients diagnosed either at our hospital or at our referral centers with angina or ischemia with nonobstructive CAD on coronary angiography were referred to a specific outpatient clinic (the NOCA clinic at Hospital Clinic, Barcelona, Spain) for a screening visit. Nonobstructive CAD was defined as angiographic evidence of normal coronary arteries or diffuse atherosclerosis with stenosis < 50% and/or fractional flow reserve (FFR) > 0.80 if there was stenosis between 50% and 70%. During the screening visit, a team of expert cardiologists confirmed patients’ eligibility for the NOCA program based on the following criteria: a) diagnosis of ANOCA, defined as stable, chronic, typical angina symptoms (eg, chest pain precipitated by physical exertion or emotional stress and relieved by rest or nitroglycerine); b) diagnosis of INOCA, defined as the demonstration of myocardial ischemia identified by a non-invasive test with pharmacologic or exercise stress tests such as cardiac single photon emission computed tomography, cardiac magnetic resonance, stress electrocardiography, or echocardiography. The exclusion criteria were: a) atypical angina symptoms, and b) clearly identifiable noncoronary causes of chest pain (figure 1). The study protocol adhered to the Declaration of Helsinki and the study was approved by our institutional review committee. All patients provided written informed consent to be included in this program and study. The clinical ethics committee gave their approval for a retrospective analysis of the collected data.

Coronary function testing was performed using a pressure-temperature sensor guidewire (PressureWire X Guidewire and Coroventis CoroFlow Cardiovascular System, Abbott Vascular, United States) placed in the left anterior descending artery (LAD) as the prespecified target vessel, reflecting its subtended myocardial mass and coronary dominance. Steady-state hyperemia was induced using intravenous adenosine (140 µg/kg/min). If there was severe tortuosity of the LAD or evidence of myocardial ischemia in a region...
other than the territory of the LAD, the wire was placed in the right coronary artery or the left circumflex, as per the operator’s decision. CFR was calculated using thermodilution, defined as resting mean transit time divided by hyperemic mean transit time (abnormal CFR was defined as ≤ 2.5). IMR was calculated as the product of distal coronary pressure at maximal hyperemia multiplied by the hyperemic mean transit time (normal value < 25). Intracoronary ACh provocation testing was performed with a standardized protocol involving serial ACh infusions for 20 seconds at increasing concentrations (2-20-100 µg in the left coronary artery with an interval of 2-3 minutes between each injection) with concomitant assessment of the patient’s symptoms, electrocardiogram documentation, and angiographic scans. Patients taking vasoactive drugs (eg, calcium channel blockers and nitrates) underwent a wash-out period of at least 48 hours before the provocative test. Epicardial coronary spasm was defined as the reproduction of chest pain and ischemic electrocardiogram changes in association with a reduction in coronary diameter ≥ 90% from baseline in any epicardial coronary artery segment. Microvascular spasm was diagnosed when typical ischemic ST-segment changes (deviation ≥ 1 mm) and angina developed in the absence of epicardial coronary constriction (< 90% diameter reduction). Subsequently, patients were stratified into 4 endotypes: a) microvascular angina (MVA) [evidence of coronary microvascular dysfunction (CMD) defined as any abnormal CFR [< 2.5], IMR [≥ 25], or microvascular spasm]; b) vasospastic angina (VSA) (CFR ≥ 2.5, IMR < 25 and epicardial spasm); c) both MVA and VSA (evidence of CMD and epicardial spasm); and d) noncoronary chest pain (CFR ≥ 2.5 and IMR < 25, with neither microvascular nor epicardial spasm). Any complications occurring during the invasive diagnostic workup were documented, including bradyarrhythmias, atrial fibrillation, ventricular tachycardia or fibrillation, coronary perforations, death from any cause, and any other complications.

NOCA program: pharmacological and psychological therapeutic approach

Once the endotype was identified, medical treatment for each patient was optimized accordingly (table 1). In patients with MVA, treatment with beta-blockers and calcium channel blockers (CCBs) was started or up-titrated. Ranolazine was added if angina symptoms were not fully controlled by beta-blockers and CCBs. In
patients with VSA, treatment with nondihydropyridine CCBs and long-acting nitrates was started or up-titrated. In patients with both MVA and VSA, treatment with nondihydropyridine CCBs or beta-blockers was started or up-titrated. In patients with noncoronary chest pain, vasoactive drugs were discontinued unless clinically indicated for other reasons. Additionally, treatment with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and statins was started or up-titrated in all patients. If a patient showed intolerance or had contraindications to a specific medication (eg, asthma for beta-blockers, perimalleolar edema for CCBs, severe bradycardia for both beta-blockers and CCBs), the treatment was tailored and modified accordingly.

Because stress is an important trigger factor for angina symptoms, all patients were also referred to a team of expert psychologists for psychological support.15

NOCA program: clinical outcome and quality of life evaluation

All patients were followed up at 1, 3, 6, and 12-months for treatment titration and assessment of clinical outcomes. At the time of coronary angiography [ie, baseline] and at the 3-month follow-up, all patients were administered the Seattle Angina Questionnaire (SAQ) and quality of life questionnaire (EuroQol-5D [EQ-5D]). The SAQ is a validated 19-item self-administered questionnaire that measures 5 dimensions of CAD: physical limitation, angina stability, angina frequency, treatment satisfaction, and disease perception.16 The EQ-5D is a standardized, nondisease-specific questionnaire used to describe and evaluate patients’ health status and was intended to complement other quality-of-life measures.17 Figure 2 provides a visual representation of all the steps involved for patients included in the NOCA program.

Statistical analysis

Data distribution was assessed according to the Kolgomorov-Smirnov test. Continuous variables were compared using the unpaired Student t-test or the Mann–Whitney U test, as appropriate. The data are expressed as mean ± standard deviation [SD] or as median and interquartile range [IQR]. Categorical data are expressed as numbers and percentages and were evaluated using the chi-square test or Fisher exact test, as appropriate. A 2-sided P value < .05 was considered significant. All analyses were performed using SPSS version 21 (SPSS; United States).

RESULTS

Baseline characteristics of the study population

From January 2021 to December 2021, a total of 77 patients were screened at the NOCA clinic for inclusion in the NOCA program. Following the screening visit, 23 (29.9%) patients were excluded from the NOCA program: 12 due to atypical angina symptoms and

Table 1. Medical therapy according to the specific endotype of ANOCA/INOCA

<table>
<thead>
<tr>
<th>Pathogenic mechanism of MINOCA</th>
<th>Therapeutic implications</th>
</tr>
</thead>
<tbody>
<tr>
<td>MVA</td>
<td>Beta-blockers (Nebivolol 2.5–10 mg daily)</td>
</tr>
<tr>
<td></td>
<td>CCBs (amlodipine 10 mg daily, or verapamil 240 mg daily, or diltiazem 90 mg twice daily)</td>
</tr>
<tr>
<td></td>
<td>Ranolazine (375-750 mg twice daily)</td>
</tr>
<tr>
<td>VSA</td>
<td>Nondihydropyridine CCBs (verapamil 240 mg, or ciltiazem 90 mg twice daily)</td>
</tr>
<tr>
<td></td>
<td>Long-acting nitrates (isosorbide mononitrate 30 mg)</td>
</tr>
<tr>
<td>MVA and VSA</td>
<td>CCBs (verapamil or diltiazem) or beta-blockers</td>
</tr>
<tr>
<td>Noncoronary chest pain</td>
<td>Beta-blockers or dihydropyridine CCBs if clinically indicated (eg, hypertension)</td>
</tr>
<tr>
<td></td>
<td>ACEi or ARB if clinically indicated</td>
</tr>
<tr>
<td></td>
<td>Statins if clinically indicated</td>
</tr>
</tbody>
</table>

ACEi, angiotensin-converting enzyme inhibitors; ANOCA, angina with no obstructed coronary arteries; ARB, angiotensin receptor blockers; CCBs, calcium channel blockers; INOCA, ischemia with no obstructed coronary arteries; MINOCA, myocardial infarction with non-obstructive coronary artery disease; MVA, microvascular angina; VSA, vasospastic angina.
due to a clearly identifiable noncoronary cause. Consequently, 54 patients were included in the NOCA program (mean age 64.4 ± 9.4 years, 39 [63.9%] women). A total of 29 (53.7%) patients had INOCA and 25 (46.3%) had ANOCA. All clinical and angiographic characteristics of the study population are shown in table 1.

The results of the invasive functional assessment are presented in table 2. The mean IMR and CFR values were 21.2 ± 10.6 and 2.3 ± 1.4, respectively. MVA was diagnosed in 19 (35.2%) patients, VSA in 12 (22.2%), and both MVA and VSA in 18 (33.3%). Finally, 5 (9.3%) patients were diagnosed with noncoronary chest pain. Among INOCA patients, MVA was diagnosed in 11 (37.9%) patients, VSA in 7 (24.1%), both MVA and VSA in 8 (27.6%), and noncoronary chest pain in 3 (10.3%). Among ANOCA patients, MVA was diagnosed in 8 (32.0%) patients, VSA in 5 (20.0%), both MVA and VSA in 10 (40.0%), and noncoronary chest pain in 2 (8.0%). There were no statistically significant differences in the prevalence of any endotype between INOCA and ANOCA patients [all \( P > .05 \), figure 3].

Complications occurred in 3 (5.5%) patients during intracoronary ACh provocation testing: 2 (3.7%) patients had transient bradycardia and 1 (1.8%) patient had paroxysmal atrial fibrillation that spontaneously reverted to sinus rhythm.

The results of the invasive functional assessment are presented in table 2. The mean IMR and CFR values were 21.2 ± 10.6 and 2.3 ± 1.4, respectively. MVA was diagnosed in 19 (35.2%) patients, VSA in 12 (22.2%), and both MVA and VSA in 18 (33.3%). Finally, 5 (9.3%) patients were diagnosed with noncoronary chest pain. Among INOCA patients, MVA was diagnosed in 11 (37.9%) patients, VSA in 7 (24.1%), both MVA and VSA in 8 (27.6%), and noncoronary chest pain in 3 (10.3%). Among ANOCA patients, MVA was diagnosed in 8 (32.0%) patients, VSA in 5 (20.0%), both MVA and VSA in 10 (40.0%), and noncoronary chest pain in 2 (8.0%). There were no statistically significant differences in the prevalence of any endotype between INOCA and ANOCA patients [all \( P > .05 \), figure 3].

Complications occurred in 3 (5.5%) patients during intracoronary ACh provocation testing: 2 (3.7%) patients had transient bradycardia and 1 (1.8%) patient had paroxysmal atrial fibrillation that spontaneously reverted to sinus rhythm.

### NOCA program: diagnosis of the specific endotype and complications

The results of the invasive functional assessment are presented in table 2. The mean IMR and CFR values were 21.2 ± 10.6 and 2.3 ± 1.4, respectively. MVA was diagnosed in 19 (35.2%) patients, VSA in 12 (22.2%), and both MVA and VSA in 18 (33.3%). Finally, 5 (9.3%) patients were diagnosed with noncoronary chest pain. Among INOCA patients, MVA was diagnosed in 11 (37.9%) patients, VSA in 7 (24.1%), both MVA and VSA in 8 (27.6%), and noncoronary chest pain in 3 (10.3%). Among ANOCA patients, MVA was diagnosed in 8 (32.0%) patients, VSA in 5 (20.0%), both MVA and VSA in 10 (40.0%), and noncoronary chest pain in 2 (8.0%). There were no statistically significant differences in the prevalence of any endotype between INOCA and ANOCA patients [all \( P > .05 \), figure 3].

Complications occurred in 3 (5.5%) patients during intracoronary ACh provocation testing: 2 (3.7%) patients had transient bradycardia and 1 (1.8%) patient had paroxysmal atrial fibrillation that spontaneously reverted to sinus rhythm.

### NOCA program: treatment optimization according to the specific endotype

Inclusion in the NOCA program led to statistically significant changes in medications after diagnosis of the specific endotype. There was a significant increase in the use of beta-blockers [33.3% before vs 57.4% after, \( P = .008 \)], non-dihydropyridine CCBs [9.3% before vs 37.0% after, \( P < .001 \)], and long-acting nitrates [46.3% before vs 63.0% after, \( P = .012 \)]. There were no statistically significant differences in any other medications before and after the
invasive assessment (all \( P > .05 \), figure 4). All changes in medications according to the specific endotype of ANOCA/INOCA are shown in figure 5.

**NOCA program: clinical outcome evaluation**

At 3 months of follow-up, there was no statistically significant difference in the mean EQ-5D score compared with baseline (64.8 \( \pm \) 18.1 at baseline vs 66.1 \( \pm \) 17.1 at 3 months of follow-up, \( P = .302 \)) (figure 6). However, there was a statistically significant improvement in the SAQ score in terms of physical limitations (59.7 \( \pm \) 19.3 at baseline vs 66.2 \( \pm \) 16.9 at 3 months of follow-up, \( P = .037 \)), angina stability (57.1 \( \pm \) 28.1 at baseline vs 75.8 \( \pm \) 22.3 at 3 months of follow-up, \( P = .010 \)), and disease perception (42.5 \( \pm \) 13.9 at baseline vs 50.8 \( \pm \) 16.3 at 3 months follow-up, \( P = .015 \)). No statistically significant difference was found in angina frequency (74.3 \( \pm \) 20.4 at baseline vs 80.7 \( \pm \) 19.8 at 3 months of follow-up, \( P = .193 \)) or treatment satisfaction (68.1 \( \pm \) 12.6 at baseline vs 70.5 \( \pm \) 12.5 at 3 months of follow-up, \( P = .950 \)) (figure 7). No events were recorded at the 1-year follow-up.

**DISCUSSION**

The main results of our experience can be summarized as follows: 
- the implementation of a specific diagnostic and therapeutic protocol [NOCA program] in patients with a previous diagnosis of nonobstructive CAD can be easily implemented in clinical practice. A key innovation of our study, compared with prior publications, is the creation and implementation of a specific protocol for the INOCA/ANOCA population. Additionally, our approach involves a screening visit with assessment by a team of expert cardiologists for patients with a suspected diagnosis of INOCA/ANOCA. This approach improves identification of such patients, and, in our experience, led to the exclusion of almost one third of patients (29.9%) due to atypical angina symptoms or no clearly identifiable coronary causes of chest pain. This is another novelty of our study that could be extremely relevant in the management of these patients. Indeed, the selection of patients to be included in the program may allow clinical resources to be directed to patients who are most likely to benefit, while avoiding repeat invasive procedures and related risks in patients with unclear indications. Additionally, the specialized counseling provided by cardiologists and nurses during the screening visit, together with psychological support, are likely to be vital components of the management of INOCA/ANOCA patients. Indeed, recent studies have demonstrated how psychological factors, such as chronic stress, anxiety, depression, and social stressors are involved in the genesis of MVA and VSA.  
- Mental stress has been demonstrated to determine CMD mainly through endothelium-dependent mechanisms and endothelial dysfunction. Similarly, by activating brain areas involved in regulation of neuroendocrine and autonomic nervous systems, mental stress can lead to hyperreactivity of vascular smooth muscle cells, autonomic nervous system dysfunction, oxidative stress, vascular inflammation, and endothelial dysfunction, resulting in an increased propensity to coronary vasospasm.
Furthermore, in line with previous studies, our experience demonstrates that performing a comprehensive invasive diagnostic assessment for the diagnosis of the specific endotype in INOCA and ANOCA patients is safe and is associated with a low rate of mild and transient complications. For all these reasons, patients and clinicians should be reassured about the lack of serious complications and cardiologists should be strongly encouraged to implement a specific diagnostic and therapeutic program in these patients. Indeed, the availability of such a program for INOCA and ANOCA patients may have significant clinical and therapeutic implications, as, in our experience, it resulted in substantial changes in medications and a marked improvement at the 3-month follow-up of the SAQ questionnaire regarding physical limitations, angina frequency, and disease perception. The lower and nonsignificant improvement in the other parameters (eg, angina frequency and treatment satisfaction) could be attributed to the already high baseline values (74.5 ± 19.9 and 69.6 ± 11.9, respectively). Similarly, the absence of a significant improvement in the EQ-5D questionnaire at 3 months might be due to the short follow-up period or the fact that it is a nondisease-specific questionnaire designed to describe and assess patients’ health status and is intended to complement other quality-of-life measures.

Study limitations

Some limitations of this study should be acknowledged. First, this is a single-center study with a relatively small sample size and short follow-up. Second, we did not perform a cost-analysis and therefore we cannot speculate on the impact of the NOCA program on health care-related costs. Further studies in larger ANOCA and INOCA populations are warranted. Finally, the absence of a control group precluded a thorough assessment of the improvement in the quality of life among these patients.
CONCLUSIONS

Our experience demonstrates that a specific diagnostic and therapeutic protocol (NOCA program) can be easily and safely implemented in routine clinical practice. Such a protocol could ensure the best care for INOCA and ANOCA patients, as well as improve their quality of life and avoid inappropriate treatments and incomplete investigations. Future evidence from randomized clinical trials or recommendations from international clinical guidelines supporting the implementation of a specific protocol in these patients are strongly warranted.

FUNDING

This study received no funding.

ETHICAL CONSIDERATIONS

The study protocol complied with the Declaration of Helsinki and the study was approved by our Institutional Review Committee. All patients gave written informed consent to be included in this program and study. The clinical ethics committee gave their approval for a retrospective analysis of the data collected. In this work, the possible variables of sex and gender have been taken into account.

STATEMENT ON THE USE OF ARTIFICIAL INTELLIGENCE

No artificial intelligence tools were used during the preparation of this work.

AUTHORS’ CONTRIBUTIONS

R. Rinaldi, F. Spione, F.M. Verardi: data extraction and analysis and manuscript drafting; R. Rinaldi, F. Spione, S. Brugaletta: design and manuscript revision; P. Vidal Calés, V. Arévalos, R. Gabani, D. Cánovas, M. Gutiérrez, M. Pardo, R. Domínguez, L. Pintor, X. Torres, X. Freixa, A. Regueiro, O. Abdul-Jawad Altisent, M. Sabaté: manuscript revision. All authors have read and agreed to the published version of the manuscript.

CONFLICTS OF INTEREST

The authors have nothing to disclose.

ACKNOWLEDGMENTS

F. Spione has been supported by a research grant provided by the Cardiopath PhD program.
WHAT IS KNOWN ABOUT THE TOPIC?

- Up to 60% to 70% of patients with angina and/or documented myocardial ischemia do not have angiographic evidence of obstructive coronary artery disease. This condition is defined as angina with no obstructed coronary arteries (ANOCA) or ischemia with no obstructed coronary arteries (INOCA) when associated with evidence of myocardial ischemia. There are still concerns about the implementation in real practice of a systematic diagnostic and therapeutic approach in INOCA and ANOCA patients, potentially impacting outcomes and quality of life.

WHAT DOES THIS STUDY ADD?

- The implementation of a specific protocol (INOCA program) in patients with a diagnosis of nonobstructive CAD is feasible and allowed parsimonious use of medical resources. A comprehensive invasive diagnostic assessment in INOCA or ANOCA patients is safe and is associated with a low rate of mild and transient complications. The availability of a specific diagnostic and therapeutic program for INOCA and ANOCA patients may have important clinical and therapeutic implications, as, in our experience, it led to significant changes in medications and a notable improvement at 3 months of follow-up in the SAQ questionnaire regarding physical limitations, angina frequency, and perception of the disease.

REFERENCES